Legend Biotech Corp. · NASDAQ:LEGN
Legend Biotech — Q2 2026 Earnings Presentation
19 slides from Legend Biotech's earnings presentation, Aug 11, 2026
Slide 1: Second Quarter 2026 Financial Results & Corporate Update
August 11, 2026 Second Quarter 2026 Financial Results & Corporate Update This presentation is for investor relations purposes only - Not for product promotional purposes 1
Slide 2: Agenda
1 Opening Remarks 2 Q2 2026 Highlights & Recent Accomplishments Agenda 3 4 Pipeline CARVYKTI® Performance Overview 5 Financial Performance 6 Q&A 2 This presentation is for investor relations purposes only - Not for product promotional purposes
Slide 3: Alan Bash and Carlos Santos
Alan Bash Carlos Santos Interim Chief Executive Officer Chief Financial Officer 3 This presentation is for investor relations purposes only - not for product promotional purposes
Slide 4: Forward-looking Statements
Forward-looking Statements This presentation has been prepared by Legend Biotech Corporation (“Legend Biotech” or the submissions with the FDA, the EMA and other regulatory authorities; expected results and “Company”) solely for information purpose and does not contain all relevant information timin
Slide 5: Non-IFRS financial metrics
Non-IFRS financial metrics This presentation refers to certain non-IFRS financial metrics. We use Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Share (which we sometimes refer to as “Adjusted EPS”, or “ANI per Share”, respectively) as performance metrics. Adjusted Net Income (Loss) a
Slide 6: Alan Bash
Alan Bash Interim Chief Executive Officer 6 This presentation is for investor relations purposes only - not for product promotional purposes
Slide 7: Q2 2026 Highlights & Recent Accomplishments
Q2 2026 Highlights & Recent Accomplishments Q2 2026 Highlights • CARVYKTI® Net Trade Sales grew 50% YoY1 $657M • 32% YoY growth in US • 128% YoY growth OUS • CARVYKTI® is launched in 19 global markets, with 3482 global activated CARVYKTI® treatment sites • At EHA 2026, established first clinical pro
Slide 8: CARVYKTI Sales Highlights
CARVYKTI® Sales Highlights Expanding market penetration and earlier-line adoption represent a substantial and durable growth opportunity CARVYKTI® Net Trade Sales ($MM) YoY Growth1 QoQ Growth2 U.S. 32% 9% +50% growth to $657M in Q2’26 vs. $439M in Q2’25 700 OUS3 128% 13% 185 Global4 50% 10% 600 164
Slide 9: Select Presentations at ASCO 2026
Select Presentations at ASCO 2026 LB2102 & CARTITUDE Program Data LB2102 - DLL3-targeted CAR-T therapy for SCLC1 & LCNEC2 • At higher dose levels, LB2102 achieved an ORR3 of 28.6% and a DCR4 of 78.6%, with durable responses observed in some patients • Demonstrated a manageable safety profile and enc
Slide 10: Promising LB2501 Efficacy Data from EHA 2026
Promising LB2501 Efficacy Data from EHA 2026 LB2501: in vivo CD19/CD20 dual-target CAR-T therapy Phase 1 study in adults with Relapsed/Refractory B-Cell NHL Response Rate DL2 (N=6) Total (N=12) RESULTS PRESENTED AT EHA1 2026 ORR, n (%) [95% CI] 6 (100) [54.1-100] 6 (50.0) [21.1-78.9] • Dose Level 2
Slide 11: Advancing a Robust, Differentiated Cell Therapy Pipeline
Advancing a Robust, Differentiated Cell Therapy Pipeline Program Target Indication Pre-Clinical Phase I Phase II Phase III NDA Current Status Partner CARVYKTI®: BCMA-directed Autologous Therapy NDMM (Front-line) (Transplant Not Intended) (CARTITUDE-5)(1) Multi-Regional Clinical Trial Patient follow-
Slide 12: Well Positioned For Long-Term Growth
Well Positioned For Long-Term Growth $657M ~$965 Million 14 Profitable1 Q2 2026 CARVYKTI Net Trade Sales Cash Position2 Pipeline Programs CAR-T Leadership in MM3 Cell Therapy Innovation Durable Global Business • CARVYKTI® is the top-selling CAR-T • Advancing next generation cell • ~$965 Million in C
Slide 13: Carlos Santos
Carlos Santos Chief Financial Officer 13 This presentation is for investor relations purposes only - not for product promotional purposes
Slide 14: Progress Towards Sustainable Profitability in 2026
Progress Towards Sustainable Profitability in 2026 Strong underlying demand growth, with Operating Margin improving from -142% in 2Q23 to 15% in 2Q26 450 150% Non-IFRS Adjusted Net Income/(Loss) (USD $M) 52% y/y Growth 400 100% 350 50% Operating Margin (%) 300 Revenue ($MM) 250 0% 200 -50% 150 -100%
Slide 15: Q2 2026 Financial Highlights
Q2 2026 Financial Highlights $ in millions (except per share) Q2 2026 Q2 2025 Change Driving Operating Leverage Over Time Collaboration Revenue 326.1 219.7 48% o Significant revenue growth of 52% YoY with License & Other Revenue 61.4 35.4 73% operating expenses growth of only 7% YoY Total Revenue 38
Slide 16: Profitability and Strong Balance Sheet for Business Sustainability
Profitability and Strong Balance Sheet for Business Sustainability 2026 Goals Investment Priorities Balance Sheet Strength • 3/4 of CARVYKTI® orders • Advancing in vivo CAR-T • ~$965 Million in Cash, Cash from 2-4L pipeline programs Equivalents and Time • Consecutive quarter over • Focused, synergis
Slide 17: Q&A
Q&A Alan Bash Carlos Santos Yuhong Qiu Interim Chief Executive Officer Chief Financial Officer Interim Head of R&D 17 This presentation is for investor relations purposes only - not for product promotional purposes
Slide 18: Thank you!
Thank you! 18 This presentation is for investor relations purposes only - Not for product promotional purposes
Slide 19: Reconciliation of IFRS to Non-IFRS Metrics
Reconciliation of IFRS to Non-IFRS Metrics Three months ended June 30, ($ in millions, except per share data) 2026 2025 Net income (loss) 33.2 (125.4) Depreciation and amortization 11.7 5.9 Share-based compensation 17.3 18.7 Impairment loss (included in other operating expense) 0.3 0 Unrealized fore